Gilead Sciences GILD
CEO: Daniel O'Day · Biotechnology · 17,000 employees
Compensation Breakdown
Compensation History
| Year | Salary | Bonus | Stock Awards | Options | Non-Equity | Other | Total |
|---|---|---|---|---|---|---|---|
| 2025 | $824K | — | $4.6M | $2.5M | $1.3M | $41K | $9.2M |
| 2024 | $808K | — | $6.1M | $1.2M | $1.8M | $193K | $10.0M |
| 2023 | $791K | $103K | $3.6M | $2.7M | $626K | $139K | $8.2M |
| 2022 | $775K | — | $5.8M | $711K | $862K | $197K | $8.6M |
All compensation data is sourced from SEC DEF 14A proxy filings submitted to EDGAR. The Economic Policy Institute's CEO pay analysis provides additional context on executive compensation trends across industries.
Named Executive Officers
Peer CEO Compensation
Frequently Asked Questions
Daniel O'Day, CEO of Gilead Sciences (GILD), earns $9.2M in total compensation. This includes base salary, stock awards, option awards, and other incentives as reported in the company's most recent DEF 14A proxy statement.
Gilead Sciences has a Pay-for-Performance Score of A (88/100). The company's 3-year total shareholder return is +50.6%, and the say-on-pay shareholder vote passed with 91.5% approval.
The CEO-to-median-worker pay ratio at Gilead Sciences is 243:1. The median worker at Gilead Sciences earns $38K per year, while CEO Daniel O'Day earns $9.2M in total compensation.
Gilead Sciences employs approximately 17,000 people. The company operates in the Biotechnology industry within the Healthcare sector, generating $27.1B in annual revenue.